Leaflet LASTET 25mg soft capsules
Indicated for: cancer
Route of administration: oral
Substance: etoposide (topoisomerase inhibitor)
ATC: L01CB01 (Antineoplastic and immunomodulating agents | Plant alkaloids and other natural products | Podophyllotoxin derivatives)
This medicine may affect fertility.
Handle with special care.
Effective contraception is required during treatment.
Do not use this medicine while breastfeeding.
Do not use this medicine during pregnancy.
This medicine may affect the liver.
This medicine may have important interactions with other medicines.
This medicine may lower blood cell counts.
This medicine is subject to additional monitoring.
Periodic laboratory tests may be required during treatment.
Stop taking the medicine and seek urgent medical help if a severe rash occurs.
Etoposide is a chemotherapy drug used to treat various types of cancer, including small cell lung cancer, testicular cancer, lymphomas, and leukemias. It belongs to a class of drugs called topoisomerase II inhibitors, which work by interfering with cell division, thereby destroying rapidly dividing cancer cells.
The mechanism of action of etoposide involves inhibiting the enzyme topoisomerase II, which is essential for DNA replication and cell division. By blocking this enzyme, etoposide causes the accumulation of DNA strand breaks, leading to cancer cell death. It is administered either intravenously or orally, depending on the type of cancer and the treatment protocol.
While effective, etoposide can cause side effects. The most common include nausea, vomiting, loss of appetite, hair loss, fatigue, and a decrease in blood cell counts (myelosuppression), which can increase the risk of infections, bleeding, and anemia. In rare cases, severe allergic reactions or other complications, such as secondary leukemia, may occur, especially with long-term use.
Etoposide must be administered under the strict supervision of an oncologist, and patients should be regularly monitored to assess their response to treatment and detect potential side effects. It is contraindicated in patients with hypersensitivity to the active substance or severe bone marrow suppression. During treatment, it is important for patients to avoid contact with sick individuals and follow their doctor's recommendations to minimize associated risks.
General data about LASTET 25mg
- Substance: etoposide
- Date of latest medicines list: 01-07-2013
- Product code: W52188001
- Concentration: 25mg
- Pharmaceutical form: soft capsules
- Quantity: 40
- Product type: Generic medicine
- Prescription status: P-RF - Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.
Pharmaceutical forms available for etoposide
Concentrations available for etoposide
- 100mg
- 100mg/5ml
- 200mg/10ml
- 20mg/ml
- 25mg
- 50mg
- 50mg/2.5ml